Regeneron And Sanofi's Dupixent Receives EU Approval For Children With Eosinophilic Esophagitis, Offering New Hope For Ages 1 To 11

瑞昱与赛诺菲安万特的Dupixent获得欧盟批准，可用于1至11岁儿童患有嗜酸性食道炎，为他们带来新希望

Benzinga · 2024/11/06 15:00

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year

批准基于第3期数据，显示相比安慕希的安慕希，12到16周岁的儿童更多使用Dupixent实现组织学疾病缓解，这种缓解持续了一年

Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial

Dupixent是欧盟首个适用于治疗这些年轻患者的药物，他们在生长至关重要的关键阶段持续难以进食

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Regeneron And Sanofi's Dupixent Receives EU Approval For Children With Eosinophilic Esophagitis, Offering New Hope For Ages 1 To 11

Regeneron And Sanofi's Dupixent Receives EU Approval For Children With Eosinophilic Esophagitis, Offering New Hope For Ages 1 To 11

风险及免责提示

声明